TW202134261A - 使用il-33拮抗劑之方法 - Google Patents

使用il-33拮抗劑之方法 Download PDF

Info

Publication number
TW202134261A
TW202134261A TW109138235A TW109138235A TW202134261A TW 202134261 A TW202134261 A TW 202134261A TW 109138235 A TW109138235 A TW 109138235A TW 109138235 A TW109138235 A TW 109138235A TW 202134261 A TW202134261 A TW 202134261A
Authority
TW
Taiwan
Prior art keywords
antagonist
egfr
abnormal
mucus
epithelial
Prior art date
Application number
TW109138235A
Other languages
English (en)
Chinese (zh)
Inventor
瑞尼亞 達格爾
克斯蒂 豪斯雷
瑪布比 蓋艾迪
山姆 史翠克森
艾瑪 蘇珊 柯翰
瑪麗亞 貝爾維西
羅斯 澤維爾 羅梅羅
Original Assignee
英商梅迪繆思有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商梅迪繆思有限公司 filed Critical 英商梅迪繆思有限公司
Publication of TW202134261A publication Critical patent/TW202134261A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW109138235A 2019-11-04 2020-11-03 使用il-33拮抗劑之方法 TW202134261A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19206984.7 2019-11-04
EP19206984 2019-11-04

Publications (1)

Publication Number Publication Date
TW202134261A true TW202134261A (zh) 2021-09-16

Family

ID=68426347

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109138235A TW202134261A (zh) 2019-11-04 2020-11-03 使用il-33拮抗劑之方法

Country Status (10)

Country Link
US (1) US20220380450A1 (cg-RX-API-DMAC10.html)
EP (1) EP4054711A1 (cg-RX-API-DMAC10.html)
JP (2) JP7843701B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220093334A (cg-RX-API-DMAC10.html)
CN (2) CN122140920A (cg-RX-API-DMAC10.html)
AU (2) AU2020379171B2 (cg-RX-API-DMAC10.html)
CA (1) CA3158323A1 (cg-RX-API-DMAC10.html)
IL (1) IL292443A (cg-RX-API-DMAC10.html)
TW (1) TW202134261A (cg-RX-API-DMAC10.html)
WO (1) WO2021089563A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2991847T3 (es) 2021-08-27 2024-12-05 Medimmune Ltd Tratamiento de enfermedad pulmonar obstructiva crónica con un anticuerpo anti-interleucina-33
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
TW202423972A (zh) 2022-08-26 2024-06-16 英商梅迪繆思有限公司 使用抗介白素－３３抗體的氣喘治療

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
NZ549040A (en) * 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
WO2008137552A2 (en) 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
WO2015032932A1 (en) * 2013-09-05 2015-03-12 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
HUE064292T2 (hu) 2013-12-26 2024-03-28 Mitsubishi Tanabe Pharma Corp Humán anti-IL-33 semlegesítõ monoklonális antitest
SG11201605580RA (en) 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
JP6929771B2 (ja) 2014-11-10 2021-09-01 ジェネンテック， インコーポレイテッド 抗インターロイキン−３３抗体及びその使用
MX387295B (es) * 2015-03-31 2025-03-18 Medimmune Ltd Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos.
SG11201808693WA (en) 2016-04-27 2018-11-29 Pfizer Anti-il-33 antibodies, compositions, methods and uses thereof
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
WO2018204598A1 (en) 2017-05-03 2018-11-08 The University Of North Carolina At Chapel Hill Methods for diagnosing or predicting chronic bronchitis

Also Published As

Publication number Publication date
US20220380450A1 (en) 2022-12-01
AU2020379171B2 (en) 2025-05-08
EP4054711A1 (en) 2022-09-14
AU2020379171A1 (en) 2022-06-09
IL292443A (en) 2022-06-01
JP2026012782A (ja) 2026-01-27
JP2023500492A (ja) 2023-01-06
JP7843701B2 (ja) 2026-04-10
AU2025213676A1 (en) 2025-08-28
KR20220093334A (ko) 2022-07-05
CA3158323A1 (en) 2021-05-14
CN122140920A (zh) 2026-06-05
WO2021089563A1 (en) 2021-05-14
CN114901361A (zh) 2022-08-12

Similar Documents

Publication Publication Date Title
CA3176518A1 (en) Methods and compositions for treating virus-associated inflammation
US20250042986A1 (en) Stem cell factor inhibitor
JP2026012782A (ja) Ｉｌ－３３アンタゴニストの使用方法
WO2016002820A1 (ja) 新規抗ヒトｏｘ４０リガンド抗体、及びこれを含む抗インフルエンザ薬
EP4499688A1 (en) Methods for reducing respiratory infections
US20220153826A1 (en) Methods and compositions for treating virus-associated inflammation
EA052516B1 (ru) Способы применения антагонистов il-33
US20220363748A1 (en) Anti il-33 therapeutic agent for treating renal disorders
HK40016017A (en) Method for modulating inflammasome activity and inflammation in the lung